# Study With CY, Pembrolizumab, GVAX Pancreas Vaccine, and SBRT in Patients With Locally Advanced Pancreatic Cancer

> **NCT02648282** · PHASE2 · COMPLETED · sponsor: **Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins** · enrollment: 58 (actual)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DRUG:** Cyclophosphamide
- **DRUG:** GVAX Pancreatic Cancer Vaccine
- **DRUG:** Pembrolizumab
- **RADIATION:** SBRT

## Key facts

- **NCT ID:** NCT02648282
- **Lead sponsor:** Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-07-18
- **Primary completion:** 2022-06-01
- **Final completion:** 2022-06-01
- **Target enrollment:** 58 (ACTUAL)
- **Last updated:** 2026-03-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02648282

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02648282, "Study With CY, Pembrolizumab, GVAX Pancreas Vaccine, and SBRT in Patients With Locally Advanced Pancreatic Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02648282. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*